Jennison Associates
FOLD

Jennison Associates’s Amicus Therapeutics FOLD Stock Holding History

Jennison Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-65,788
Closed -$707K – 624
2022
Q2 		$707K Sell
65,788
-3,502,726
-98% -$28.8M ﹤0.01% 558
2022
Q1 		$33.8M Sell
3,568,514
-1,816,756
-34% -$17M 0.02% 280
2021
Q4 		$62.2M Sell
5,385,270
-285,771
-5% -$3.18M 0.04% 187
2021
Q3 		$54.2M Sell
5,671,041
-90,644
-2% -$927K 0.04% 206
2021
Q2 		$55.5M Buy
5,761,685
+28,206
+0.5% +$275K 0.04% 210
2021
Q1 		$56.6M Buy
5,733,479
+1,030,896
+22% +$16M 0.04% 201
2020
Q4 		$109M Sell
4,702,583
-657,222
-12% -$13.4M 0.08% 100
2020
Q3 		$75.7M Buy
5,359,805
+274,966
+5% +$4.01M 0.06% 122
2020
Q2 		$76.7M Sell
5,084,839
-23,271
-0.5% -$284K 0.07% 113
2020
Q1 		$47.2M Sell
5,108,110
-2,104,111
-29% -$20M 0.06% 150
2019
Q4 		$70.2M Buy
7,212,221
+9,089
+0.1% +$83.2K 0.07% 154
2019
Q3 		$57.8M Sell
7,203,132
-660,878
-8% -$7.17M 0.06% 176
2019
Q2 		$98.1M Sell
7,864,010
-760,927
-9% -$9.66M 0.1% 121
2019
Q1 		$117M Sell
8,624,937
-1,199,435
-12% -$14.7M 0.12% 103
2018
Q4 		$94.1M Sell
9,824,372
-247,592
-2% -$2.72M 0.11% 114
2018
Q3 		$122M Sell
10,071,964
-22,803
-0.2% -$319K 0.11% 114
2018
Q2 		$158M Sell
10,094,767
-240,700
-2% -$3.64M 0.15% 85
2018
Q1 		$155M Buy
10,335,467
+633,354
+7% +$9.64M 0.15% 81
2017
Q4 		$140M Sell
9,702,113
-69,912
-0.7% -$961K 0.14% 104
2017
Q3 		$147M Buy
9,772,025
+838,267
+9% +$11.1M 0.15% 94
2017
Q2 		$90M Sell
8,933,758
-101,909
-1% -$820K 0.1% 169
2017
Q1 		$64.4M Sell
9,035,667
-242,243
-3% -$1.53M 0.07% 224
2016
Q4 		$46.1M Buy
9,277,910
+1,371,434
+17% +$9.49M 0.05% 276
2016
Q3 		$58.5M Buy
7,906,476
+2,759,262
+54% +$18.6M 0.06% 260
2016
Q2 		$28.1M Buy
5,147,214
+6,168
+0.1% +$43.1K 0.03% 366
2016
Q1 		$43.4M Buy
5,141,046
+1,017,091
+25% +$7.2M 0.05% 304
2015
Q4 		$40M Buy
4,123,955
+133,138
+3% +$1.2M 0.04% 324
2015
Q3 		$55.8M Buy
3,990,817
+618,822
+18% +$9.71M 0.06% 281
2015
Q2 		$47.7M Buy
+3,371,995
New +$40.5M 0.04% 346

Other funds holding FOLD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates's FOLD Position: Q3 2022 in Review

Jennison Associates sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 65,788 shares — an estimated $707K sold.

Jennison Associates first reported a position in FOLD in Q2 2015 and held it in 29 quarters. The position peaked at $158M in Q2 2018. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

  • Jennison Associates reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jennison Associates sold 65,788 Amicus Therapeutics shares in Q3 2022, an estimated $707K.
  • Jennison Associates first reported a position in Amicus Therapeutics in Q2 2015 and held it in 29 quarters.
  • Jennison Associates's Amicus Therapeutics position peaked at $158M in Q2 2018.
  • 222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Jennison Associates's 13F filing for Q3 2022, filed 1 Nov 2022.